Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine

키워드

참고문헌 (23)

1. Siegel R, "Cancer statistics, 2014", CA Cancer J Clin, 64, pp.9~29 (2014)
2. Lee HY, "Melanoma : differences between Asian and Caucasian patients", Ann Acad Med Singapore, 41, pp.17~20 (2012)
3. Ishihara K, "Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update", Int J Clin Oncol, 13, pp.33~41 (2008)
4. Comis RL, "DTIC(NSC-45388)in malignant melanoma : a perspective", Cancer Treat Rep, 60, pp.165~176 (1976)
5. Atkins MB, "High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma : analysis of 270patients treated between 1985 and 1993", J Clin Oncol, 17, pp.2105~2116 (1999)
6. Rao RD, "Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma", Cancer, 106, pp.375~382 (2006)
7. Flaherty KT, "Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma", J Clin Oncol, 31, pp.373~379 (2013)
8. Mhaidat NM, "Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2", Mol Cancer Ther, 6, pp.752~761 (2007)
9. Mhaidat NM, "Docetaxelinduced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1", 2 pathway, 2007, pp.13, 1308~1314
10. Hotchkiss KA, "Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel(Taxotere) : association with impaired repositioning of the microtubule organizing center", Mol Cancer Ther, 1, pp.1191~1200 (2002)
11. Grant DS, "Comparison of antiangiogenic activities using paclitaxel(taxol)and docetaxel(taxotere)", Int J Cancer, 104, pp.121~129 (2003)
12. Curtin JA, "Distinct sets of genetic alterations in melanoma", N Engl J Med, 353, pp.2135~2147 (2005)
13. Griewank KG, "Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas", Clin Cancer Res, 19, pp.3143~3152 (2013)
14. Perrin C, "Metastatic melanoma : results of 'classical' second-line treatment with cytotoxic chemotherapies", J Dermatolog Treat, 25, pp.396~400 (2014)
15. Eisen T, "Results of a multicenter, randomized, double-blind phase 2", 3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma, 2010, pp.116, 146~154
16. Hauschild A, "Results of a phase III, randomized, placebocontrolled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma", J Clin Oncol, 27, pp.2823~2830 (2009)
17. Singh AD, "Uveal melanoma : trends in incidence, treatment, and survival", Ophthalmology, 118, pp.1881~1885 (2011)
18. Diener-West M, "Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26", Arch Ophthalmol, 123, pp.1639~1643 (2005)
19. Bhatia S, "Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma:SWOG S0512", PLoS One, 7, pp.e48787~ (2012)
20. Carvajal RD, "Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma : a randomized clinical trial", JAMA, 311, pp.2397~2405 (2014)
21. Schmittel A, "Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma", Melanoma Res, 15, pp.205~207 (2005)
22. Van Raamsdonk CD, "Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi", Nature, 457, pp.599~602 (2009)
23. Van Raamsdonk CD, "Mutations in GNA11 in uveal melanoma", N Engl J Med, 363, pp.2191~2199 (2010)

관련 논문AI추천